DolPHIN 2 is a groundbreaking brand that aims to address the challenges surrounding mother-to-child transmission of HIV. Despite global prevention efforts, this remains a significant route of HIV infection, especially in sub-Saharan Africa. DolPHIN 2 focuses on preventing HIV transmission from infected pregnant women to their infants.

The brand is conducting a clinical trial called DolPHIN 2 to assess the effectiveness of a new antiretroviral drug called Dolutegravir (DTG) compared to the current standard therapy, Efavirenz (EFV). The trial aims to recruit 250 late-presenting HIV-positive pregnant women and randomize them into two groups to receive either DTG or EFV-containing combination antiretroviral therapy (cART). The primary goal is to achieve undetectable HIV viral load at delivery, which reduces the risk of vertical transmission of HIV.

In addition to the clinical trial, DolPHIN 2 also includes qualitative and pharmacoeconomic studies to support the implementation of Dolutegravir. The brand is led by a consortium of researchers and partners in Europe and sub-Saharan Africa, including the University of Liverpool, Liverpool School of Tropical Medicine, Infectious Diseases Institute, University of Cape Town, Radboud University Medical Centre, and Unitaid. DolPHIN 2's mission is to generate high-quality evidence and provide operational guidance for the use of Dolutegravir in reducing mother-to-child transmission of HIV, ultimately contributing to the global goal of eliminating this preventable transmission